Abstract
Angiogenesis, the growth of new blood vessels from pre-existing vasculature, plays an important role in physiological and pathological conditions. For this reason, the study of different anti-angiogenic drugs and its improvement is spread around the world. Nanotechnology gives novel opportunities to the development of new drugs. Based on nanosized systems, nanotechnology applied in medicine can improve the diagnosis and the treatment of the great majority of diseases. Nanomedicine has been applied in diagnosis, imaging and in drug delivery systems. Specifically in angiogenesis, researchers have developed new angiogenesis targeted nanosystems and have demonstrated that they can improve the diagnosis and the treatment of different diseases in areas like oncology, cardiology and ophthalmology.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Aukunuru JV, Ayalasomayajula SP, et al. (2003) Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells. J Pharm Pharmacol 55(9):1199–1206.
Cormode DP, Skajaa T, et al. (2009) Nanotechnology in medical imaging: probe design and applications. Arterioscler Thromb Vasc Biol 29(7):992–1000.
Jani PD, Singh N, et al. (2007) Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest Ophthalmol Vis Sci 48(5):2030–2036.
Kim JH, Kim YS, et al. (2008) Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy. Biomaterials 29(12):1920–1930.
Kubo M, Egashira K, et al. (2009) Therapeutic neovascularization by nanotechnology-mediated cell-selective delivery of pitavastatin into the vascular endothelium. Arterioscler Thromb Vasc Biol 29(6):796–801.
Marano RJ, Toth I, et al. (2005) Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a log-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther 12(21):1544–50.
Mukherjee P, Bhattacharya R, et al. (2005) Antiangiogenic properties of gold nanoparticles. Clin Cancer Res 11(9):3530–3534.
Mulder WJ, Castermans K, et al. (2009) Molecular imaging of tumor angiogenesis using alphavbeta3-integrin targeted multimodal quantum dots. Angiogenesis 12(1):17–24.
Murphy EA, Majeti BK, et al. (2008) Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci USA 105(27):9343–8.
Slegers TP, van Rooijen N, et al. (2000) Delayed graft rejection in pre-vascularized corneas after subconjunctival injection of clodronate liposomes. Curr Eye Res 20(4):322–4.
Tamayi Y (2009) Prospects for nanomedicine in treating age-related macular degeneration. Nanomed 4(3):341–352.
Waters, EA, Chen J, et al. (2008) Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS. J Cardiovasc Magn Reson 10(1):43.
Winter PM, Caruthers SD, et al. (2008) Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc Imaging 1(5):624–34.
Winter PM, Morawski AM, et al. (2003) Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 108(18):2270–2274.
Winter PM, Neubauer AM, et al. (2006) Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol 26(9):2103–2109.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Cuadal, J.S., Morral, M., Ramis-Castelltort, M. (2010). “Overview on Nanotechnology and Angiogenesis in Major Diseases Processes”. In: Slevin, M. (eds) Therapeutic Angiogenesis for Vascular Diseases. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-9495-7_19
Download citation
DOI: https://doi.org/10.1007/978-90-481-9495-7_19
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-9494-0
Online ISBN: 978-90-481-9495-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)